Meeting
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
Authors
Grace Wei
USF Health Morsani College of Medicine, Tampa, FL
Grace Wei , Marilin Rosa , Maxine Chang , Brian J. Czerniecki , Xia Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Genetics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10526)
DOI
10.1200/JCO.2021.39.15_suppl.10526
Abstract #
10526
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Neal A. Fischbach
Poster
2023 ASCO Annual Meeting
Spectrum of germline pathogenic variants among patients with cancer in Mexico.
First Author: Jose Luis Rodriguez Olivares
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2019 ASCO Annual Meeting
Prevalence and penetrance of breast cancer-associated mutations identified by multiple-gene sequencing in the Women’s Health Initiative.
First Author: Allison W. Kurian